Immunomodulation has been an interesting phenomenon among immunologists since immunopotentiation could enhance immunity against infection or tumors, whereas immunosupression or anti-inflammatory manipulation can be used to control autoimmunity or diseases caused by aberrant or hyper-reactive immune responses. Sepsis is caused by hyper-responsiveness of the immune system, in which the mortality rate is as high as 50% ([@B1]). In septic conditions, large amount of pro-inflammatory cytokines is produced rapidly. Therefore, the early innate response of the immune system to pathogens plays a critical role in septic conditions. Toll-like receptors (TLRs) are important pattern recognition receptors (PRRs) that participate in the innate immune response. TLR4, in conjunction with CD14, acts as the receptor for lipopolysaccharide (LPS), a component of Gram-negative bacteria cell walls ([@B2]). TLR2 recognizes peptidoglycan and lipoteichoic acid (LTA) in Gram-positive bacteria cell walls ([@B3]). Activation of TLR2 or TLR4 through binding of their ligands leads to NF-κB activation and transcription of many genes, including typical pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and IL-6 as well as several chemokines that recruit leukocytes into the site of inflammation ([@B4],[@B5]).

CKD-712 has been developed as an anti-inflammatory agent targeting sepsis. CKD-712 is a higenamine derivative (1-alpha-naphthylmethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline), also referred to as YS 49. It has been shown that CKD-712 reduced NO production in macrophage cells and increased survival rates in mice after LPS treatment ([@B6],[@B7]). Furthermore inhibition of the Janus activated kinase (JAK)-2/signal transducer and activators of transcription (STAT)-1 pathway by CKD-712 has been reported to decrease levels of iNOS, cyclooxygenase-2, and hemeoxygenase-1 in macrophage cells ([@B8]). More recently, CKD-712 was found to suppress the secretion of high-mobility group box 1 (HMGB-1) via inhibition of phosphatidylinositol 3 (PI3K)-protein kinase C (PKC) signaling after LTA or LPS stimulation in macrophage cells ([@B9]).

In this study we attempted to determine which signaling pathway is affected by CKD-712 after TLR4 stimulation, since TLR4 is the major PRRs responsible in development of sepsis.

HEK293-TLR4 cells (kindly provided by Professor Douglas T. Golenbock, Massachusetts University, USA) were cultured in 10% fetal bovine serum-RPMI1640 medium. HEK293-TLR4 cells express MD2 and CD14 as well. CKD-712 was kindly provided by ChongKunDang Pharm, Cheonan. LPS was purchased from Sigma-Aldrich, St. Louis, MI, USA. To assess cell viability after treatment of CKD-712, cells were reacted with 5 mg/ml of tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT) (Sigma-Aldrich). After 3 hrs of incubation (37℃, 5% CO~2~) the medium containing MTT was removed and 200µl of DMSO was added into the well and the absorbance was measured at 540 nm. For the luciferase assay. 2×10^5^ cells/well were seeded in 12-well plates and cultured for 2 days. NF-κB promoter and pCMV β-gal vector were co-transfected overnight, and CKD-712 was pre-treated before LPS treatment. LPS was treated for 6 hrs. Luciferase activity was measured by a Luciferase Reporter Assay System (Promega, Madison, WI, USA) and β-galactosidase activity was measured with O-nitrophenyl-β-D-galactopyranoside (Sigma-Aldrich), as the substrate. Luciferase activity was normalized for transfection efficiency with the β-galactosidase activity. Western blotting was done using anti-TLR4, anti-ERK, anti-p38, anti-JNK, anti-IRF3 or anti-Akt antibodies as well as control antibodies. All of the antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA).

First, we determined the optimal concentration of CKD-712 in HEK293-TLR4 cells. When treated with CKD-712 for 24 hrs the cell viability was 50% at 100µM and 40% at 200µM ([Fig. 1A](#F1){ref-type="fig"}). Next, HEK293-TLR4 cells were treated with LPS and NF-κB activation was measured. CKD-712 was pre-treated 1 hr before stimulation of LPS. We found that 50µM of CKD-712 inhibited NF-κB activation in TLR4 signaling. When treated with 50µM of CKD-712, NF-κB activation decreased to less than 100,000 RIU (25 ng/ml of LPS) and 200,000 RIU (50 ng/ml of LPS) when compared to 200,000 RIU and 500,000 RIU, respectively in control groups ([Fig. 1B](#F1){ref-type="fig"}).

Next, we investigated whether treatment with CKD-712 modulates MAP kinaseactivation. After stimulation with LPS, CKD-712 did not inhibit activation of ERK, JNK or p38 kinase in HEK293-TLR4 cells ([Fig. 2](#F2){ref-type="fig"}). Rather, pre-treatment with CKD-712 delayed activation of these kinases. As shown in [Fig. 3](#F3){ref-type="fig"}, MAP kinases were phosphorylated 15\~30 min following stimulation with LPS, after which activation subsided in 60 min. However, CKD-712 treatment extended the activation of ERK and JNK, which were found to be activated 60 min after TLR4 stimulation ([Fig. 2](#F2){ref-type="fig"}). Phosphorylation of IRF3 was not inhibited and showed a sustained activation like the MAP kinases ([Fig. 2](#F2){ref-type="fig"}). Interestingly, the activation of Akt was augmented slightly with pre-treatment of CKD-712 (50µM) after LPS stimulation ([Fig. 3](#F3){ref-type="fig"}, left). But higher concentration of CKD-712 (100µM) inhibited the activation of Akt completely ([Fig. 3](#F3){ref-type="fig"}, right).

With the brief data presented here, we suggest that CKD-712 activated Akt and MAP kinases after TLR4 stimulation at 50µM. Emerging evidence has shown the existence of a close relation between TLRs and the PI3K/Akt pathway. One of the early evidences demonstraetd that PI3-kinase is involved in TLR4-mediated cytokine expression in mouse macrophages ([@B10]). Even in non-immune cells, such as, in foam cells, binding of LPS and TLR4 increases Nox1 expression through the phospholipase A~2~ β-Akt signaling pathway ([@B11]). Another paper reporting that HMGB-1 induced migration of vascular smooth muscle cells in the TLR4-dependent PI3K/Akt pathway also suggests a strong involvement of PI3K/Akt in the TLR4 signaling pathway ([@B12]).

But the PI3K-Akt-mTOR-p70 S6k pathway is also known to be a negative regulator of MyD88-dependent intracellular signals after TLR stimulation. TLR4-mediated signaling leads to rapid activation of PI3K and phosphorylation of Akt, a downstream target of PI3K in mouse macrophages, in which the sustained interaction of MyD88/PI3K with the TLR4 intracellular \"signaling platform\" negatively regulates further MyD88 dependent signaling ([@B13]). The administration of the TLR2 ligand, Pam^3^CSK^4^, was found to significantly increase the levels of phosphorylation of Akt, which lead to significant protection in a cerebral injury model, suggesting that the PI3 kinase-Akt pathway is involved with TLR2 signaling as well as TLR4 signaling ([@B14]). More recently the association of endogenous TBK1 and Akt was observed in macrophages when stimulated with poly (I:C) and LPS, showing that Akt activation mediated by TBK1 contributes to TLR3 and TLR4-mediated immune responses ([@B15]).

The effect of CKD-712 on phosphorylation of Akt depends on the cell types. In immune cells, CKD-712 inhibits Akt activation in macrophages ([@B9]) and human endothelial cells ([@B15]). But in rat heart muscle cells, CKD-712 enhances Akt activation to prevent myocardical ischemia and further inflammation ([@B16]). Our data show that in HEK293 cells, CKD-712 at low concentration augments the activation of Akt, whereas high concentration of CKD-712 has an inhibiting effect. Therefore pharmaceutical agents regulating the PI3-Akt pathway may be used as immunomodulators in the innate immune response. Although the mechanism of the augmented activation of Akt by CKD-712 and the inhibition of NF-κB activation have yet to be clarified, CKD-712 still has a potential as an immunomodulator.
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![Effect of CKD-712 on TLR4 signaling. (A) To assess CKD-712 toxicity HEK293-TLR4 cells (2×10^5^) were cultured with CKD-712 for 24 hrs and cell viability was determined by MTT assay. (B) To evaluate the effect of CKD-712 on NF-κB activation 2×10^5^ HEK-TLR4 cells/well were seeded in 12-well plates and were cultured for 2 days. Then NF-κB promoter and pCMV β-gal vector were co-transfeceted overnight and CKD-712 (50µM) was pre-treated before LPS treatment. LPS was treated for 6 hrs. After measuring luciferase activity and β-galactosidase activity the luciferase activity was normalized for transfection efficiency with the β-galactosidase activity.](in-11-420-g001){#F1}

![Effect of CKD-712 on activation of MAP kinases and IRF3 in TLR4 signaling. HEK293-TLR4 cells were stimulated with LPS (50 ng/ml). Western blot was performed anti-ERK, anti-JNK, anti-p38 or anti-IRF3 antibodies. CKD-712 (50µM) was pre-treated 1 hr before LPS stimulation. Three independent experiments were performed and the representative data are shown.](in-11-420-g002){#F2}

![Effect of CKD-712 on Akt activation in TLR4 signaling. HEK293-TLR4 cells were stimulated with LPS (50 ng/mL) and western blot was performed with anti-Akt antibodies. CKD-712 (50 or 100µM) was pretreated 1 hr before LPS stimulation. Two independent experiments were performed and the representative data are shown. The density was measures by densitometry and relative ratio of p-Akt/Akt in study groups was calculated based on the p-Akt/Akt of control group as 1.0.](in-11-420-g003){#F3}
